A $38.7 million project in the European Union — the largest single grant for autism research in the world — aims to bring together academic labs and pharmaceutical companies to speed the move from basic to clinical research.
Spectrum: Autism Research News
Efforts to ease the symptoms of autism are beginning to ramp up, with promising candidates in various stages of testing.
Preliminary results from a placebo-controlled trial of the antibiotic minocycline in children with fragile X syndrome suggest the drug alleviates some aspects of the disorder, according to research presented Friday at the International Meeting for Autism Research in Toronto.
Toddlers with autism who receive behavioral interventions that improve joint attention — engaging and following others’ focus — have better language ability five years later than do controls, according to a study published in May in the Journal of the American Academy of Child and Adolescent Psychiatry.
The past few years have seen an unprecedented number of clinical trials for experimental drugs to treat autism-related disorders, most notably for fragile X syndrome. But as the trials progress, scientists are calling for better methods to measure the drugs’ effectiveness.
A genetic defect in the synthesis of carnitine, a molecule that is essential for proper mitochondrial function, might slightly increase risk for autism in some children, according to research published 8 May in the Proceedings of the National Academy of Sciences.